

2018 ISV ANNUAL CONGRESS

28th-30th OCTOBER • ATLANTA, GA



ORAL PROGRAM			
SUNDAY OCTOBER 28, 2018			
08:00-09:15	REGISTRATION		
08:30-09:45	WELCOME COFFEE (<i>Marquis Foyer</i>)		SPONSORED BY: <u>GlaxoSmithKline (GSK)</u>
09:45-09:55	CONGRESS CO-CHAIRS OPENING REMARKS (<i>Marquis Salon A</i>) ISV Congress co-Chairs: Ted Ross, <i>University of Georgia</i> ; Denise Doolan, <i>James Cook University</i>		
9:55-10:00	INTRODUCTION OF OPENING SESSION AND SPEAKER (<i>Marquis Salon A</i>) David Weiner, <i>ISV President</i>		
10:00-10:45	Creating Vaccine Confidence: Courage, Conviction, and Compassion (<i>Marquis Salon A</i>) Julie Gerberding, <i>Merck and Co.</i> and <i>US CDC Director (2002-2009)</i>		
10:45-12:00	PLENARY SESSION 1: <u>Influenza 1918 to 2018</u> (<i>Marquis Salon A</i>) Session Chairs: Ted Ross, <i>University of Georgia</i> ; Rafi Ahmed, <i>Emory University</i>		
10:45-11:10	[PL1.1] Where did the Spanish Influenza come from and could its killing power have been thwarted by the "new" vaccines in 1918? John Oxford, <i>Queen Mary College</i>		
11:10-11:35	[PL1.2] Pathogenesis of the 1918 Pandemic Virus Terrence Tumpey, <i>Centers for Disease Control and Prevention</i>		
11:35-12:00	[PL1.3] Influenza Vaccine Effectiveness: What's the Problem with H3N2? Edward Belongia, <i>Marshfield Clinic Research Institute</i>		
12:00-13:30	LUNCH (<i>Skyline – 10th Floor</i>)		SPONSORED BY: <u>INOVIO PHARMACEUTICALS</u>
13:30-15:45	CONCURRENT SESSION 1 <u>Vaccine Technologies, Formulations, and Delivery</u> <i>(International 8)</i> Session Chairs: Mark Prausnitz, <i>Georgia Tech University</i> Karl Ljungberg, <i>Karolinska Institutet</i>	CONCURRENT SESSION 2 <u>Neoantigens, Cancer Vaccines, and More</u> <i>(International 9)</i> Session Chairs: Nikolai Petrovsky, <i>Flinders University</i> Randy Albrecht, <i>Mount Sinai School of Medicine</i>	CONCURRENT SESSION 3 <u>Non-Viral Vaccines</u> <i>(International 10)</i> Session Chairs: Linda Klavinskis, <i>King's College London</i> Suh-Chin Wu, <i>National Tsing Hua University</i>
13:30-13:55	[O1.1] Developing Vaccines that Elicit Broadly Neutralizing Antibodies Ravi Kane, <i>Georgia Tech University</i>	[O2.1] Immunogenicity of Neoantigen Cancer Vaccines Hyewon Phee, <i>Amgen</i>	[O3.1] Toward licensure of the first and future generations of live parasite <i>Plasmodium falciparum</i> sporozoite (PfSPZ) vaccines Thomas Richie, <i>Sanaria</i>
13:55-14:20	[O1.2] Microneedle Patch as a New Vaccine Delivery Method Nadine Roupheal, <i>Emory University</i>	[O2.2] Advances in the field of in-silico methods for the identification of (neo)epitopes. Morten Nielsen, <i>The Technical University of Denmark</i>	[O3.2] Autophagy: a New Strategy for Host-directed Therapy of Tuberculosis Eun-Kyoung Jo, <i>Chungnam National University School of Medicine</i>
14:20-14:35	[O1.3] Immunogenicity of a protective intradermal DNA vaccine against Lassa Virus in <i>Cynomolgus</i> Jingjing Jiang, <i>Inovio Pharmaceuticals</i>	[O2.3] Beyond Adjuvants: Vaccines for Cancer Immunotherapy and Infectious Disease Young Taik Lim, <i>Sungkyunkwan University</i> →(14:20-14:45)←	[O3.3] Replicating Single Cycle Adenovirus Vaccine against <i>Clostridium Difficile</i> William Matchett, <i>Mayo Clinic</i>

14:35-14:50	[O1.4] Genomic DNA as a damage - associated molecular pattern increases the immunogenicity of influenza vaccines given by a dissolvable microneedle patch Teena Mohan, <i>Georgia State University</i>	[O2.4] Development of a novel multi-level anti-cancer vaccine using mimotopes of anti-Her-2/neu antibodies in combination with immune checkpoint inhibitors Joshua Tobias, <i>Medical University of Vienna</i> →(14:45-15:00)←	[O3.4] Vaccine-induced immunity in the immunocompromised host: Evaluating antifungal vaccine efficacy in a non-human primate model of drug-induced immunosuppression Viviana Cobos Jimenez, <i>University of Georgia</i>
14:50-15:05	[O1.5] A Single-cycle Adenovirus Vaccine against Ebola Virus Stephanie Anguiano-Zarate, <i>Mayo Clinic</i>	[O2.5] Development of Vaccines for Infectious Diseases and Cancer Using a Novel MVA-VLP Vector Arban Domi, <i>GeoVax, Inc.</i> →(15:00-15:15)←	[O3.5] To what Extent Are Recent Pertussis Epidemics Due to Under Vaccination or to Waning of Pertussis Vaccine Immunity? Ousseny Zerbo, <i>Kaiser Permanente</i>
15:05-15:20	[O1.6] Immunogenicity and Efficacy of a Thermostable Live-Attenuated Influenza Vaccine in Ferrets Jasmina Luczo, <i>University of Georgia</i>	[O2.6] Longitudinal Assessment of Memory B cell and Plasmablast Reactivity Against Influenza A Hemagglutinin in Subjects of Varying Age Rodrigo Abreu, <i>University of Georgia</i> →(15:15-15:30)←	[O3.6] Microneedle-based Novel Transdermal Gonorrhoea Vaccines Lotika Bajaj, <i>Mercer University</i>
15:20-15:35	[O1.7] Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses Lei Deng, <i>Georgia State University</i>	[O2.7] A DNA-based immunotherapy induces receptor-blocking antibodies that can neutralize HBV in humanized mice Lars Frelin, <i>Karolinska Institutet</i> →(15:30-15:45)←	[O3.7] Design of a multi-antigenic, multi-stage and multi-epitope potential vaccine candidate against onchocerciasis and related filarial diseases: adding immunoinformatics to immunomics Robert Adamu Shey, <i>Universite Libre de Bruxelles</i>
15:45-16:15	COFFEE BREAK (<i>Marquis Foyer/Marquis Salon B</i>) SPONSORED BY: GEORGIA RESEARCH ALLIANCE		
16:15-18:10	PLENARY SESSION 2: <u>Host Immune Response to Vaccination</u> (<i>Marquis Salon A</i>) Session Chairs: Shan Lu, <i>UMass Medical School</i> ; Maria Issagouliantis, <i>Riga Stradins University</i>		
16:15-16:40	[PL2.1] Vaccines and Immune Memory Rafi Ahmed, <i>Emory University</i>		
16:40-17:05	[PL2.2] Profiling the IgOme - the repertoire of antibodies in serum: <i>principles and applications</i> Johnathan Gershoni, <i>Tel Aviv University</i>		
17:05-17:30	[PL2.3] Understanding Innate Immune Mechanisms Dictating Vaccine Responses Karen Loré, <i>Karolinska Institutet</i>		
17:30-17:55	[PL2.4] The History of Pertussis and Pertussis Vaccines; Mistakes Made during a 112-Year Odyssey and What some of those Mistakes Bode for the Future James Cherry, <i>University of California, Los Angeles</i>		
17:55-18:10	[PL2.5] Skin immunisation harnesses networks of protective immune connectivity in peripheral tissues Linda Klavinskis, <i>King's College London</i>		
18:10-20:00	POSTER SESSION # 1 (<i>Marquis Salon B</i>)		
18:30-20:00	WELCOME RECEPTION (<i>Marquis Foyer/Marquis Salon B</i>)		SPONSORED BY: EpiVax, Inc.

MONDAY OCTOBER 29, 2018			
07:30-08:30	MORNING COFFEE (<i>Marquis Foyer</i>)		SPONSORED BY: <u>MERCK</u>
08:30-10:10	PLENARY SESSION 3: <u>Human Vaccine Trials</u> (<i>Marquis Salon A</i>) Session Chairs: Julia Hilliard, <i>Georgia State University</i> ; Annie DeGroot, <i>EpiVax, Inc.</i>		
08:30-08:55	[PL3.1] The State of Vaccine Development Against the Human Cytomegalovirus Stanley Plotkin, <i>Vaxconsult</i>		
08:55-09:20	[PL3.2] Lymphoid tissue fibrosis is associated with impaired vaccine responses Tim Schacker, <i>University of Minnesota</i>		
09:20-09:45	[PL3.3] Vaccines for Herpes Zoster Tony Cunningham, <i>The Westmead Institute for Medical Research and University of Sydney</i>		
09:45-10:10	[PL3.4] Systems Biology in Vaccine Trials Nadine Roupheal, <i>Emory University</i>		
10:10-10:40	COFFEE BREAK (<i>Marquis Foyer/Marquis Salon B</i>)		SPONSORED BY: <u>GC PHARMA</u>
10:40-12:30	CONCURRENT SESSION 4 <u>Viral Vaccines</u> <i>(International 8)</i> Session Chairs: Mark Connors, <i>NIAID</i> Lars Frelin, <i>Karolinska Institutet</i>	CONCURRENT SESSION 5 <u>E-RID Vaccines</u> <i>(International 9)</i> Session Chairs: Ed Rybicki, <i>University of Cape Town</i> Paul Duprex, <i>Boston University School of Medicine</i>	CONCURRENT SESSION 6 <u>Vaccine Evaluation</u> <i>(International 10)</i> Session Chairs: Jeffrey Ulmer, <i>GlaxoSmithKline</i> Karen Norris, <i>University of Georgia</i>
10:40-11:05	[O4.1] A Replication Defective Human Cytomegalovirus as a Vaccine for Prevention of Congenital Infection Tong Ming Fu, <i>Merck Research Laboratories</i>	[O5.1] Innovative vaccination methods Gary Kobinger, <i>Université Laval</i>	[O6.1] CD40L-adjuvanted HIV Vaccines Induce Broad Neutralizing Antibody Responses in Macaques Rama Rao Amara, <i>Emory University</i>
11:05-11:30	[O4.2] Engineering immunogenicity: novel live attenuated vaccines against pneumoviruses Martin Moore, <i>Meissa Vaccines</i>	[O5.2] Rift Valley Fever control through vaccination: an ongoing challenge in endemic regions Baptiste Dingu, <i>MCI Sante Animale</i>	[O6.2] Development of therapeutic vaccines for cardiovascular diseases Hironori Nakagami, <i>Osaka University</i>
11:30-11:45	[O4.3] Efficacy of RSV Maternal Immunization Varies with the Version of the Pre-fusion F Antigen in Virus-like Particles (VLPs) Trudy Morrison, <i>University of Massachusetts Medical School</i>	[O5.3] Towards the development of influenza virus vaccines: insights from the ferret animal model Randy Albrecht, <i>Icahn School of Medicine at Mount Sinai</i>	[O6.3] Is the current dose of normal human immunoglobulin for post-exposure prophylaxis of measles in Australia too low? Megan Young, <i>Griffith University</i>
11:45-12:00	[O4.4] Novel RSV vaccine development protect adult and neonate animals Bin Wang, <i>Fudan University</i>	[O5.4] Age-Related Modulation of Immune Response to Vaccination with a Chikungunya Virus-Like Particle Vaccine and Chikungunya Viral Infection Maria Arevalo, <i>University of Georgia</i>	[O6.4] Variation in direct and indirect effectiveness and total impact of infant rotavirus vaccination among children in the United States: analysis of national claims data from 2001-2016 Julia Baker, <i>Emory University</i>

12:00-12:15	[O4.5] Unraveling the respiratory syncytial virus (RSV) antibody functional repertoire in adult healthy donors Emanuele Andreano, <i>University of Siena (IT)</i>	[O5.5] A Universal Dengue Vaccine Elicits Neutralizing Antibodies Against Strains from All Four Dengue Serotypes Naoko Uno, <i>University of Georgia</i>	[O6.5] Estimating the population-level effect of pediatric norovirus vaccination: A model simulation study Elizabeth Sajewski, <i>Emory University</i>
12:15- 12:30	[O4.6] Elicitation of protective antibodies against 20 years of future H3N2 co-circulating influenza virus variants in ferrets imprinted to historical H3N2 influenza viruses James Allen, <i>University of Georgia</i>	[O5.6] Multiroute morbillivirus entry: disease informs delivery Paul Duprex, <i>Boston University School of Medicine</i>	[O6.6] Status of Immunity against Polio Virus among Individuals in Three Regions of Ghana, 2017. Joseph Opare, <i>Ghana Health Service/ Ministry of Health</i>
12:30-13:30	LUNCH (<i>Skyline – 10th Floor</i>)		SPONSORED BY: <u>VGXI, Inc.</u>
13:00-14:30	POSTER SESSION # 2		(<i>Marquis Salon B</i>)
14:00-15:00	ISV ANNUAL MEETING		(<i>Marquis Salon A</i>)
15:00-15:30	COFFEE BREAK (<i>Marquis Foyer/Marquis Salon B</i>)		SPONSORED BY: <u>HIVE</u>
15:30-17:50	PLENARY SESSION 4: <u>Vaccines for Influenza Viruses</u> Session Chairs: Mark Tompkins, <i>University of Georgia</i> ; Sang-Moo Kang, <i>Georgia State University</i>		(<i>Marquis Salon A</i>)
15:30-15:55	[PL.4.1] Systems Profiling of Fluzone™ Vaccines – Biomarkers of Breadth & Durability Harold Kleanthous, <i>Sanofi Pasteur</i>		
15:55-16:20	[PL.4.2] New insights into mucosal vaccine adjuvant functions that can be explored for developing broadly protective influenza vaccines Nils Lycke, <i>University of Gothenburg</i>		
16:20-16:35	[PL.4.3] VaxArray Neuraminidase: A new assay for neuraminidase quantification of seasonal influenza vaccines Rose Nash, <i>InDevR</i>		
16:35-16:50	[PL.4.4] An alternative strategy as a quadrivalent live attenuated influenza virus vaccine Zhimin Wan, <i>University of Georgia</i>		
16:50-17:05	[PL.4.5] Molecular Dissection of the Antibody Response Elicited by a Computationally Optimized Broadly Reactive Antigen (COBRA) H1 Hemagglutinin Influenza Vaccine Giuseppe Andrea Sautto, <i>University of Georgia</i>		
17:05-17:20	[PL.4.6] Pan-influenza A protection by prime-boost vaccination with X-31 cold-adapted live attenuated influenza vaccine Baik Seong, <i>Yonsei University</i>		
17:20-17:35	[PL.4.7] Development of paradigm-shifting T cell-targeting universal influenza vaccines Daniel Hoft, <i>Saint Louis University</i>		
17:35-17:50	[PL.4.8] Robust Cellular Immune Responses and Cross-Protective Anti-Hemagglutination Responses Elicited by Influenza Micro-Consensus DNA Vaccines Anna Slager, <i>Inovio Pharmaceuticals</i>		
17:50-18:20	BUS PICK UP FOR GALA DINNER (<i>Main Entrance</i>)		
18:30-22:00	GALA DINNER (<i>TICKETS REQUIRED</i>)		SPONSORED BY: <u>VGXI, Inc.</u> and <u>GEORGIA RESEARCH ALLIANCE</u>

TUESDAY OCTOBER 30, 2018

07:30-08:30	MORNING COFFEE (<i>Marquis Foyer</i>) SPONSORED BY: <u>CELLULAR TECHNOLOGY LIMITED (CTL)</u>		
08:30-10:10	PLENARY SESSION 5: <u>Public Health, Public Policy, and Vaccine Acceptance</u> (<i>Marquis Salon A</i>) Session Chairs: Margaret Liu, <i>ProTherImmune</i> ; David Weiner, <i>The Wistar Institute</i>		
08:30-08:55	[PL5.1] Vaccine hesitancy – the global landscape Pauline Patterson, <i>London School of Hygiene & Tropical Medicine (LSHTM)</i>		
08:55-09:20	[PL5.2] Fostering Vaccine and Immunization Acceptance: Insights from Communication Practice and Research Glen Nowak, <i>University of Georgia</i>		
09:20-09:45	[PL5.3] Vaccine associated-hypersensitivity Michael McNeil, <i>Centers for Disease Control and Prevention</i>		
09:45-10:10	[PL5.4] Global strategy of Polio eradication: Russian experience Aydar Ishmukhametov, <i>Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products</i>		
10:10-10:40	COFFEE BREAK (<i>Marquis Foyer/Marquis Salon B</i>) SPONSORED BY: <u>SANOPI PASTEUR</u>		
10:40-12:20	<p style="text-align: center;">CONCURRENT SESSION 7 <u>Immunomodulators and Vaccines</u> <i>(International 8)</i> Session Chairs: Ali Harandi, <i>University of Gothenburg</i> Joon Haeng Rhee <i>Chonnam National University Medical School</i></p>	<p style="text-align: center;">CONCURRENT SESSION 8 <u>One Health and Vet Vaccines</u> <i>(International 9)</i> Session Chairs: Anna-Lise Williamson, <i>University of Cape Town</i> Jarrod Mousa, <i>University of Georgia</i></p>	<p style="text-align: center;">CONCURRENT SESSION 9 <u>HIV/AIDS</u> <i>(International 10)</i> Session Chairs: Janet McNicholl, <i>Centers for Disease Control and Prevention</i> Barbara Felber, <i>National Cancer Institute</i></p>
10:40-11:05	<p style="text-align: center;">[07.1] Vaccination against chronic diseases using virus-like particles Martin Bachmann, <i>Jenner Institute</i></p>	<p style="text-align: center;">[08.1] Nanoparticle technologies that help drive bovine immune responses in East Coast fever vaccine development Vish Nene, <i>International Livestock Research Institute (ILRI)</i></p>	<p style="text-align: center;">[09.1] Humoral responses to HIV-1: building the paths to a protective vaccine Guido Ferrari, <i>Duke University School of Medicine</i></p>
11:05-11:20	<p style="text-align: center;">[07.2] A Multi-Omics Systems Analysis of Human Vaccine Adjuvants: Of Clouds and Clocks Ali Harandi, <i>University of Gothenburg</i></p>	<p style="text-align: center;">[08.2] African Horse Sickness Virus-Like Particle Vaccine Candidate Made in Plants Edward Rybicki, <i>Biopharming Research Unit, University of Cape Town</i></p>	<p style="text-align: center;">[09.2] Needle-free injection of the sublingual and buccal tissues with an HIV-1 vaccine induces strong systemic and mucosal immune responses and protects from SHIV challenge in rhesus macaques Andrew Jones, <i>Emory University</i></p>
11:20-11:35	<p style="text-align: center;">[07.3] Human clinical data on use of Advax delta inulin adjuvants in infectious disease, allergy and cancer vaccines Nikolai Petrovsky, <i>Flinders University</i></p>	<p style="text-align: center;">[08.3] Vaccination and intra-cage transmission of a recombinant parainfluenza virus 5 expressing Rabies lyssavirus glycoprotein in the big brown bat (<i>Eptesicus fuscus</i>) Kelsey Briggs, <i>University of Georgia</i></p>	<p style="text-align: center;">[09.3] DNA+Protein HIV vaccine protection against SHIV challenge upon same site administration in macaques Barbara Felber, <i>National Cancer Institute</i></p>

11:35-11:50	[07.4] Vaccine adjuvant effects of dendritic cell-targeting peptides Yasuo Yoshioka, <i>Osaka University</i>	[08.4] Rational design of Lumpy Skin Disease Virus Vaccines Anna-Lise Williamson, <i>University of Cape Town</i>	[09.4] Direct Detection of Cross-clade ADCC activities in human volunteer sera elicited by a polyvalent DNA prime-protein boost HIV vaccine DP6-001 Shixia Wang, <i>University of Massachusetts Medical School</i>
11:50-12:05	[07.5] Cellular and Humoral Immune Responses to PENNVAX-GP® HIV DNA Vaccine plus IL-12 are Equivalent or Superior when Delivered by Intradermal vs. Intramuscular Electroporation in Healthy, HIV Uninfected Adults Srilatha Edupuganti, <i>Emory University</i>	[08.5] Laser-assisted skin delivery of immuno-contraceptive rabies nanoparticulate vaccine in poloxamer gel Amit Bansal, <i>Mercer University</i>	[09.5] Synthetic DNA Delivery by Electroporation Promotes Robust in vivo Post-Translational Modification of Broadly Neutralizing anti-HIV Immunoadhesin Ziyang Xu, <i>Wistar Institute</i>
12:05-12:20	[07.6] Augmentation of antigenicity of the C-terminal region of Clostridium perfringens enterotoxin by fusion with the B subunit of Escherichia coli Shiga toxin 2 for the development of bivalent food poisoning vaccine Koji Hosomi <i>National Institutes of Biomedical Innovation, Health and Nutrition</i>	[08.6] Identification of candidate Coxiella burnetii T cell epitopes for a novel human Q fever vaccine Lenny Moise, <i>EpiVax</i>	[09.6] Liposome-Encapsulated HIV-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans Mangala Rao, <i>USMHRP Walter Reed Army Institute of Research</i>
12:20-13:20	LUNCH (<i>Skyline – 10th Floor</i>)		
13:20-14:00	Career Development Panel (<i>International 8</i>)		
14:00-14:30	ISV Award Ceremony (<i>Marquis Salon A</i>)		
14:30-16:00	PLENARY SESSION 6: <u>The Future of Vaccines</u> (<i>Marquis Salon A</i>) Session Chairs: Denise Doolan, <i>James Cook University</i> ; Trudy Morrison, <i>University of Massachusetts Medical School</i>		
14:30-14:55	[PL6.1] Nasal Vaccines for the Prevention of Respiratory Infection Hiroshi Kiyono, <i>University of Tokyo</i>		
14:55-15:10	[PL6.2] Stabilized HIV-1 Envelope Designs Expressed in a Replication Competent Ad4 Vector Directly Impact Envelope Conformation, Expression, and Immunogenicity Mark Connors, <i>NIAID</i>		
15:10-15:25	[PL6.3] An mRNA based trivalent genital herpes vaccine: Sterilizing immunity as a real possibility Harvey Friedman, <i>University of Pennsylvania</i>		
15:25-15:40	[PL6.4] Why Are CD8 T Cell Epitopes of Human Influenza Virus Conserved? Zheng-Rong Li, <i>Emory University</i>		
15:40-15:55	[PL6.5] Pandemic Influenza Preparedness: Thailand as part of Global Action Plan to be one of the local Influenza Vaccine Development Punnee Pitisuttithum, <i>Mahidol University</i>		
16:00-16:15	CLOSING REMARKS AND INTRODUCTION TO 2019 CONGRESS (<i>Marquis Salon A</i>)		

